Michael Morabito
Stock Analyst at Chardan Capital
(0.03)
# 4,401
Out of 4,761 analysts
11
Total ratings
9.09%
Success rate
-28.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Morabito
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKRO Akero Therapeutics | Maintains: Buy | $79 → $81 | $50.58 | +60.14% | 2 | Mar 17, 2021 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Buy | $202 → $203 | $351.03 | -42.17% | 2 | Feb 26, 2021 | |
| DRRX DURECT | Maintains: Buy | $70 → $80 | $0.81 | +9,776.54% | 2 | Feb 3, 2021 | |
| ETNB 89bio | Maintains: Buy | $59 → $95 | $10.96 | +766.79% | 3 | Sep 15, 2020 | |
| VKTX Viking Therapeutics | Maintains: Buy | $15 → $20 | $31.63 | -36.77% | 2 | Aug 31, 2020 |
Akero Therapeutics
Mar 17, 2021
Maintains: Buy
Price Target: $79 → $81
Current: $50.58
Upside: +60.14%
Madrigal Pharmaceuticals
Feb 26, 2021
Maintains: Buy
Price Target: $202 → $203
Current: $351.03
Upside: -42.17%
DURECT
Feb 3, 2021
Maintains: Buy
Price Target: $70 → $80
Current: $0.81
Upside: +9,776.54%
89bio
Sep 15, 2020
Maintains: Buy
Price Target: $59 → $95
Current: $10.96
Upside: +766.79%
Viking Therapeutics
Aug 31, 2020
Maintains: Buy
Price Target: $15 → $20
Current: $31.63
Upside: -36.77%